BrainChild Bio is a clinical-stage biotechnology company focused on developing innovative therapies for pediatric patients with tumors in the central nervous system (CNS) using CAR-T cell technology. This approach involves engineering a patient's own T cells to recognize and attack cancer cells, offering a targeted treatment option that aims to improve outcomes for children suffering from cancer. The company is dedicated to addressing the unmet medical needs of pediatric patients, who have historically been overlooked in the development of commercialized medicines, and is committed to expanding its technology platform to include adult indications in the future.

The mission of BrainChild Bio is to advance scientific discovery in the field of oncology, particularly for children. By prioritizing the development of CAR-T therapies specifically for pediatric tumors, the company seeks to provide families with more effective treatment options and improve the overall landscape of cancer care for younger patients. The founder, Dr. Michael Jensen, emphasizes the importance of this work, highlighting the need for innovative solutions that cater to the unique challenges faced by children with cancer.

United States

We are a kids-first, clinical-stage biotechnology company focused on harnessing the power of CAR-T cell technology for tumors n the central nervous system (CNS), prioritizing pediatrics with plans to expand our technology to adult indications. 

We are building a platform to optimize the application of CAR-T technology in CNS tumors-- prioritizing diffuse intrinsic pontine glioma (DIPG) with plans to expand to other pediatric and adult brain tumors, including brain metastases.

BrainChild Bio

Company Details